PDF(Pubmed)
Abstract：
BACKGROUND: Heart failure (HF) patients commonly experience obstructive sleep apnea (OSA), which may worsen their condition. We reviewed a diverse range of studies to investigate the prevalence of OSA in HF patients, the effects of positive airway pressure (PAP) treatment, and the potential impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and sacubitril/valsartan on OSA outcomes.
METHODS: We analyzed case-control, observational studies, and randomized controlled trials. Prevalence rates, PAP treatment, and HF pharmacotherapy were assessed.
RESULTS: Numerous studies revealed a high prevalence of OSA in HF patients, particularly with preserved ejection fraction. PAP treatment consistently improved an apnea-hypopnea index, left ventricular ejection fraction, oxygen saturation, and overall quality of life. Emerging evidence suggests that SGLT2i and sacubitril/valsartan might influence OSA outcomes through weight loss, improved metabolic profiles, and potential direct effects on upper airway muscles.
CONCLUSIONS: The complex interplay between OSA and HF necessitates a multifaceted approach. PAP treatment has shown promising results in improving OSA symptoms and HF parameters. Additionally, recent investigations into the effects of HF pharmacotherapy on OSA suggest their potential as adjunctive therapy. This review provides insights for clinicians and researchers, highlighting the importance of addressing OSA and HF in patient management strategies.
METHODS: We analyzed case-control, observational studies, and randomized controlled trials. Prevalence rates, PAP treatment, and HF pharmacotherapy were assessed.
RESULTS: Numerous studies revealed a high prevalence of OSA in HF patients, particularly with preserved ejection fraction. PAP treatment consistently improved an apnea-hypopnea index, left ventricular ejection fraction, oxygen saturation, and overall quality of life. Emerging evidence suggests that SGLT2i and sacubitril/valsartan might influence OSA outcomes through weight loss, improved metabolic profiles, and potential direct effects on upper airway muscles.
CONCLUSIONS: The complex interplay between OSA and HF necessitates a multifaceted approach. PAP treatment has shown promising results in improving OSA symptoms and HF parameters. Additionally, recent investigations into the effects of HF pharmacotherapy on OSA suggest their potential as adjunctive therapy. This review provides insights for clinicians and researchers, highlighting the importance of addressing OSA and HF in patient management strategies.
摘要：
背景：心力衰竭（HF）患者通常会经历阻塞性睡眠呼吸暂停（OSA），这可能会使他们的病情恶化。我们回顾了各种研究，以调查HF患者中OSA的患病率，气道正压通气（PAP）治疗的效果，以及钠-葡萄糖协同转运蛋白-2抑制剂(SGLT2i)和沙库巴曲/缬沙坦对OSA结局的潜在影响。
方法：我们分析了病例对照，观察性研究，和随机对照试验。患病率,PAP治疗，和HF药物治疗进行评估。
结果：大量研究表明，OSA在HF患者中的患病率很高，特别是保留的射血分数。PAP治疗持续改善呼吸暂停低通气指数，左心室射血分数,氧饱和度,和整体生活质量。新出现的证据表明，SGLT2i和沙库巴曲/缬沙坦可能通过减肥影响OSA结果，改善代谢概况，以及对上呼吸道肌肉的潜在直接影响。
结论：OSA和HF之间复杂的相互作用需要多方面的方法。PAP治疗在改善OSA症状和HF参数方面显示出有希望的结果。此外,最近对HF药物治疗对OSA的影响进行的研究表明，它们具有辅助治疗的潜力。这篇综述为临床医生和研究人员提供了见解，强调在患者管理策略中解决OSA和HF的重要性。
方法：我们分析了病例对照，观察性研究，和随机对照试验。患病率,PAP治疗，和HF药物治疗进行评估。
结果：大量研究表明，OSA在HF患者中的患病率很高，特别是保留的射血分数。PAP治疗持续改善呼吸暂停低通气指数，左心室射血分数,氧饱和度,和整体生活质量。新出现的证据表明，SGLT2i和沙库巴曲/缬沙坦可能通过减肥影响OSA结果，改善代谢概况，以及对上呼吸道肌肉的潜在直接影响。
结论：OSA和HF之间复杂的相互作用需要多方面的方法。PAP治疗在改善OSA症状和HF参数方面显示出有希望的结果。此外,最近对HF药物治疗对OSA的影响进行的研究表明，它们具有辅助治疗的潜力。这篇综述为临床医生和研究人员提供了见解，强调在患者管理策略中解决OSA和HF的重要性。
